Fresolimumab Biosimilar – Anti-TGFB, TGF beta mAb – Research Grade

Description of Fresolimumab Biosimilar - Anti-TGFB, TGF beta mAb - Research Grade

Introduction

Fresolimumab Biosimilar, also known as Anti-TGFB or TGF beta mAb, is a research grade monoclonal antibody that targets the transforming growth factor beta (TGF-β) protein. This antibody has shown promising potential in various therapeutic applications due to its ability to inhibit the activity of TGF-β, a key cytokine involved in numerous physiological and pathological processes.

Structure of Fresolimumab Biosimilar

Fresolimumab Biosimilar is a recombinant, fully humanized IgG4 monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing a variable region that specifically binds to TGF-β. The antibody has a unique structure that allows it to bind to TGF-β with high affinity and block its signaling activity.

Activity of Fresolimumab Biosimilar

TGF-β is a multifunctional cytokine that plays a crucial role in regulating cell growth, differentiation, and immune response. However, dysregulation of TGF-β signaling has been linked to various diseases, including cancer, fibrosis, and autoimmune disorders. Fresolimumab Biosimilar acts by binding to TGF-β and preventing its interaction with its receptors, thus inhibiting downstream signaling pathways. This leads to the suppression of TGF-β-mediated effects, such as cell proliferation, migration, and inflammation.

Application of Fresolimumab Biosimilar

1.

Cancer therapy: TGF-β has been shown to promote tumor growth, invasion, and metastasis. Therefore, inhibiting its activity with Fresolimumab Biosimilar has been investigated as a potential treatment for various cancers. Clinical trials have demonstrated the efficacy of this antibody in reducing tumor growth and improving survival in patients with advanced solid tumors.

2. Fibrosis treatment: TGF-β is also a key mediator of fibrosis, a pathological process characterized by excessive accumulation of extracellular matrix proteins. Fresolimumab Biosimilar has shown promising results in preclinical studies as a potential treatment for fibrotic diseases, such as systemic sclerosis and idiopathic pulmonary fibrosis.

3.

Autoimmune disorders: TGF-β has a dual role in regulating the immune system, acting as both an anti-inflammatory and pro-inflammatory cytokine. In autoimmune disorders, TGF-β promotes the production of autoantibodies and inflammatory cytokines, leading to tissue damage. Fresolimumab Biosimilar has shown potential in inhibiting TGF-β-mediated inflammation and reducing disease severity in animal models of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

4. Wound healing: TGF-β plays a crucial role in wound healing by promoting the formation of new blood vessels and stimulating the production of extracellular matrix proteins. However, excessive TGF-β activity can lead to impaired wound healing and scarring. Fresolimumab Biosimilar has been investigated as a potential treatment for chronic wounds and keloids, where it can inhibit TGF-β and promote proper wound healing.

Conclusion

Fresolimumab Biosimilar, also known as Anti-TGFB or TGF beta mAb, is a research grade monoclonal antibody with a unique structure and high affinity for TGF-β. Its ability to inhibit TGF-β signaling has shown promising potential in various therapeutic applications, including cancer therapy, fibrosis treatment, autoimmune disorders, and wound healing. Further research and clinical trials are needed to fully explore the potential of this antibody in treating these diseases.

Fresolimumab Biosimilar - Anti-TGFB, TGF beta mAb binds to Human TGFB1/TGF-beta-1 in indirect ELISA Assay

Immobilized TGFB1 recombinant protein (cat. No. PX-P5187) at 0.5µg/mL (100µL/well) can bind Fresolimumab Biosimilar - Anti-TGFB, TGF beta mAb (cat. No. PX-TA1128) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 217.5M.